Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01945775




Registration number
NCT01945775
Ethics application status
Date submitted
11/09/2013
Date registered
19/09/2013
Date last updated
20/01/2022

Titles & IDs
Public title
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Scientific title
A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE
Secondary ID [1] 0 0
C3441009
Secondary ID [2] 0 0
673-301
Universal Trial Number (UTN)
Trial acronym
EMBRACA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Neoplasms 0 0
BRCA 1 Gene Mutation 0 0
BRCA 2 Gene Mutation 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - talazoparib
Treatment: Drugs - Physician's-Choice

Experimental: talazoparib - Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days

Active comparator: Physician's-Choice - Capecitabine, Eribulin, Gemcitabine or Vinorelbine


Treatment: Drugs: talazoparib
Until progression or unacceptable toxicity develops

Treatment: Drugs: Physician's-Choice
Capecitabine, Eribulin, Gemcitabine or Vinorelbine
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment
Timepoint [1] 0 0
Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)
Secondary outcome [1] 0 0
Percentage of Participants With Objective Response: Investigator Assessment
Timepoint [1] 0 0
Baseline until radiologic progressive disease or death due to any cause (up to a maximum duration of 36.9 months)
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Baseline until death due to any cause or analysis cut-off, up to a maximum duration of 61.4 months
Secondary outcome [3] 0 0
Trough Plasma Talazoparib Concentrations
Timepoint [3] 0 0
Predose on Day 1 of Cycle 2, 3 and 4
Secondary outcome [4] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [4] 0 0
Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months
Secondary outcome [5] 0 0
Number of Participants With Grade 3 or 4 Post-baseline Toxicities in Laboratory Parameters: Hematology
Timepoint [5] 0 0
Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months.
Secondary outcome [6] 0 0
Number of Participants With Grade 3 or 4 Post-baseline Toxicities in Laboratory Parameters: Chemistry
Timepoint [6] 0 0
Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months
Secondary outcome [7] 0 0
Number of Participants With Potentially Clinically Significant Changes From Baseline in Vital Signs
Timepoint [7] 0 0
Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months
Secondary outcome [8] 0 0
Number of Participants Taking At-least One Concomitant Medication
Timepoint [8] 0 0
Talazoparib: Baseline up to a maximum duration of 71.3 months; Physician's Choice Treatment: Baseline up to maximum duration of 46.1 months

Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed carcinoma of the breast
* Locally advanced breast cancer that is not amenable to curative radiation or surgical cure and/or metastatic disease appropriate for systemic single cytotoxic chemotherapy
* Documentation of a deleterious, suspected deleterious, or pathogenic germline BRCA1 or BRCA2 mutation from Myriad Genetics or other laboratory approved by the Sponsor
* No more than 3 prior chemotherapy-inclusive regimens for locally advanced and/or metastatic disease (no limit on prior hormonal therapies or targeted anticancer therapies such as mechanistic target of rapamycin (mTOR) or CDK4/6 inhibitors, immune-oncology agents, tyrosine kinase inhibitors, or monoclonal antibodies against CTL4 or VEGF)
* Prior treatment with a taxane and/or anthracycline in the neoadjuvant, adjuvant, locally advanced, or metastatic setting unless medically contraindicated
* Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1
* Eastern Cooperative Oncology Group (ECOG) performance status = 2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* First-line locally advanced and/or metastatic breast cancer with no prior adjuvant chemotherapy unless the Investigator determines that one of the 4 cytotoxic chemotherapy agents in the control arm would otherwise be offered to the subject
* Prior treatment with a PARP inhibitor (not including iniparib)
* Not a candidate for treatment with at least 1 of the treatments of protocol-specific physician's choice (ie, capecitabine, eribulin, gemcitabine, vinorelbine)
* Subjects who had objective disease progression while receiving platinum chemotherapy administered for locally advanced or metastatic disease; subjects who received low-dose platinum therapy administered in combination with radiation therapy are not excluded
* Subjects who have received platinum in the adjuvant or neoadjuvant setting are eligible; however, subjects may not have relapsed within 6 months of the last dose of prior platinum therapy
* Cytotoxic chemotherapy within 14 days before randomization
* Radiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days before randomization
* HER2 positive breast cancer
* Active inflammatory breast cancer
* CNS metastases

* Exception: Adequately treated brain metastases documented by baseline CT or MRI scan that has not progressed since previous scans and that does not require corticosteroids (except prednisone = 5 mg/day or equivalent) for management of CNS symptoms. A repeat CT or MRI following the identification of CNS metastases (obtained at least 2 weeks after definitive therapy) must document adequately treated brain metastases.
* Subjects with leptomeningeal carcinomatosis are not permitted
* Prior malignancy except for any of the following:

* Prior BRCA-associated cancer as long as there is no current evidence of the cancer
* Carcinoma in situ or non-melanoma skin cancer
* A cancer diagnosed and definitively treated = 5 years before randomization with no subsequent evidence of recurrence
* Known to be human immunodeficiency virus positive
* Known active hepatitis C virus, or known active hepatitis B virus
* Known hypersensitivity to any of the components of talazoparib

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/10/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/03/2021
Sample size
Target
Accrual to date
Final
431
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [2] 0 0
ICON Cancer Care (Haematology And Oncology Clinics Of Australasia (Hoca))-Milton - Milton
Recruitment hospital [3] 0 0
Icon Cancer Care, Corporate Office - South Brisbane
Recruitment hospital [4] 0 0
ICON Cancer Care - South Brisbane
Recruitment hospital [5] 0 0
ICON Cancer Foundation - South Brisbane
Recruitment hospital [6] 0 0
Mater Adult Hospital - South Brisbane
Recruitment hospital [7] 0 0
Icon Cancer Care South Brisbane - South Brisbane
Recruitment hospital [8] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [9] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [10] 0 0
Adelaide Cancer Centre - Kurralta Park
Recruitment hospital [11] 0 0
Ashford Cancer Centre Research - Kurralta Park
Recruitment hospital [12] 0 0
Cancer Care SA PTY Ltd - Kurralta Park
Recruitment hospital [13] 0 0
Cancer Care SA trading as Icon Pharmacy Adelaide - Kurralta Park
Recruitment hospital [14] 0 0
Victoria Breast and Oncology Care - East Melbourne
Recruitment hospital [15] 0 0
Peninsula & South Eastern Haematology and Oncology Group - Frankston
Recruitment hospital [16] 0 0
Barwon Health, University Hospital Geelong - Geelong
Recruitment hospital [17] 0 0
Austin Health, Heidelberg Repatriation Hospital (radiology (MUGA)scans only) - Heidelberg West
Recruitment hospital [18] 0 0
Austin Health, The Austin Hospital - Melbourne
Recruitment hospital [19] 0 0
Slade Pharmacy Mount Waverley - Mount Waverley
Recruitment hospital [20] 0 0
Nova Pharmacy - Wendouree
Recruitment hospital [21] 0 0
Ballarat Oncology & Haematology Services Clinical Trials Unit - Wendouree
Recruitment hospital [22] 0 0
Ballarat Oncology & Haematology Services - Wendouree
Recruitment hospital [23] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [24] 0 0
Sir Charles Gairdner Hospital Lung Institute Of Western Australia - Nedlands
Recruitment hospital [25] 0 0
River City Pharmacy - Auchenflower
Recruitment hospital [26] 0 0
Icon Cancer Care - Milton
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
4064 - Milton
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
4104 - South Brisbane
Recruitment postcode(s) [5] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [6] 0 0
5042 - Bedford Park
Recruitment postcode(s) [7] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [8] 0 0
3002 - East Melbourne
Recruitment postcode(s) [9] 0 0
3199 - Frankston
Recruitment postcode(s) [10] 0 0
3220 - Geelong
Recruitment postcode(s) [11] 0 0
3081 - Heidelberg West
Recruitment postcode(s) [12] 0 0
3084 - Melbourne
Recruitment postcode(s) [13] 0 0
3149 - Mount Waverley
Recruitment postcode(s) [14] 0 0
3353 - Wendouree
Recruitment postcode(s) [15] 0 0
3355 - Wendouree
Recruitment postcode(s) [16] 0 0
6150 - Murdoch
Recruitment postcode(s) [17] 0 0
6009 - Nedlands
Recruitment postcode(s) [18] 0 0
4066 - Auchenflower
Recruitment postcode(s) [19] 0 0
4066 - Milton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Mississippi
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Belgium
State/province [24] 0 0
Gent
Country [25] 0 0
Belgium
State/province [25] 0 0
Liege
Country [26] 0 0
Brazil
State/province [26] 0 0
RJ
Country [27] 0 0
Brazil
State/province [27] 0 0
RS
Country [28] 0 0
Brazil
State/province [28] 0 0
SP
Country [29] 0 0
France
State/province [29] 0 0
Besancon
Country [30] 0 0
France
State/province [30] 0 0
LYON cedex 08
Country [31] 0 0
France
State/province [31] 0 0
Marseille
Country [32] 0 0
France
State/province [32] 0 0
Nantes BP 20215
Country [33] 0 0
France
State/province [33] 0 0
Paris
Country [34] 0 0
France
State/province [34] 0 0
Saint Herblain
Country [35] 0 0
France
State/province [35] 0 0
Strasbourg
Country [36] 0 0
France
State/province [36] 0 0
Toulouse
Country [37] 0 0
France
State/province [37] 0 0
Tours Cedex 9
Country [38] 0 0
France
State/province [38] 0 0
Villejuif Cedex
Country [39] 0 0
Germany
State/province [39] 0 0
Bavaria
Country [40] 0 0
Germany
State/province [40] 0 0
Saxony
Country [41] 0 0
Germany
State/province [41] 0 0
Berlin
Country [42] 0 0
Germany
State/province [42] 0 0
Duesseldorf
Country [43] 0 0
Germany
State/province [43] 0 0
Erlangen
Country [44] 0 0
Germany
State/province [44] 0 0
Essen
Country [45] 0 0
Germany
State/province [45] 0 0
Freiburg
Country [46] 0 0
Germany
State/province [46] 0 0
Leer
Country [47] 0 0
Germany
State/province [47] 0 0
Munich
Country [48] 0 0
Germany
State/province [48] 0 0
Rostock
Country [49] 0 0
Germany
State/province [49] 0 0
Ulm
Country [50] 0 0
Ireland
State/province [50] 0 0
Dublin 4
Country [51] 0 0
Ireland
State/province [51] 0 0
Dublin 7
Country [52] 0 0
Ireland
State/province [52] 0 0
Galway
Country [53] 0 0
Israel
State/province [53] 0 0
Beer Sheva
Country [54] 0 0
Israel
State/province [54] 0 0
Haifa
Country [55] 0 0
Israel
State/province [55] 0 0
Petach Tikva
Country [56] 0 0
Israel
State/province [56] 0 0
Tel Aviv
Country [57] 0 0
Israel
State/province [57] 0 0
Tel Hashomer
Country [58] 0 0
Israel
State/province [58] 0 0
Tel-Aviv
Country [59] 0 0
Israel
State/province [59] 0 0
Zerifin
Country [60] 0 0
Italy
State/province [60] 0 0
AV
Country [61] 0 0
Italy
State/province [61] 0 0
MI
Country [62] 0 0
Italy
State/province [62] 0 0
Monza AND Brianza
Country [63] 0 0
Italy
State/province [63] 0 0
Monza Brianza
Country [64] 0 0
Italy
State/province [64] 0 0
PA
Country [65] 0 0
Italy
State/province [65] 0 0
PI
Country [66] 0 0
Italy
State/province [66] 0 0
RM
Country [67] 0 0
Italy
State/province [67] 0 0
VR
Country [68] 0 0
Italy
State/province [68] 0 0
Bologna
Country [69] 0 0
Italy
State/province [69] 0 0
Milano
Country [70] 0 0
Italy
State/province [70] 0 0
Roma
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Gyeonggi-do
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Daegu
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Incheon
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Seoul
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Ulsan
Country [76] 0 0
Poland
State/province [76] 0 0
LODZ Province
Country [77] 0 0
Poland
State/province [77] 0 0
Dobra
Country [78] 0 0
Poland
State/province [78] 0 0
Gdansk
Country [79] 0 0
Poland
State/province [79] 0 0
Gliwice
Country [80] 0 0
Poland
State/province [80] 0 0
Katowice
Country [81] 0 0
Poland
State/province [81] 0 0
Otwock
Country [82] 0 0
Poland
State/province [82] 0 0
Poznan
Country [83] 0 0
Poland
State/province [83] 0 0
Szczecin
Country [84] 0 0
Poland
State/province [84] 0 0
Warszawa
Country [85] 0 0
Russian Federation
State/province [85] 0 0
Leningrad Region
Country [86] 0 0
Russian Federation
State/province [86] 0 0
Petrozavodsk
Country [87] 0 0
Russian Federation
State/province [87] 0 0
St. Petersburg
Country [88] 0 0
Spain
State/province [88] 0 0
Avila
Country [89] 0 0
Spain
State/province [89] 0 0
Badalona Barcelona
Country [90] 0 0
Spain
State/province [90] 0 0
Barcelona
Country [91] 0 0
Spain
State/province [91] 0 0
Castellon
Country [92] 0 0
Spain
State/province [92] 0 0
Jaen
Country [93] 0 0
Spain
State/province [93] 0 0
La Coruna
Country [94] 0 0
Spain
State/province [94] 0 0
La Laguna Santa Cruz De Tenerife
Country [95] 0 0
Spain
State/province [95] 0 0
Lleida
Country [96] 0 0
Spain
State/province [96] 0 0
Madrid
Country [97] 0 0
Spain
State/province [97] 0 0
Pozuelo De Alarcon (Madrid)
Country [98] 0 0
Spain
State/province [98] 0 0
Sabadell Barcelona
Country [99] 0 0
Spain
State/province [99] 0 0
Sevilla
Country [100] 0 0
Taiwan
State/province [100] 0 0
Changhua
Country [101] 0 0
Taiwan
State/province [101] 0 0
Taipei
Country [102] 0 0
Ukraine
State/province [102] 0 0
Kriviy Rig
Country [103] 0 0
Ukraine
State/province [103] 0 0
Sumy
Country [104] 0 0
United Kingdom
State/province [104] 0 0
England
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Nottinghamshire
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Brighton
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Leeds
Country [108] 0 0
United Kingdom
State/province [108] 0 0
London
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Medivation, Inc.
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations.
Trial website
https://clinicaltrials.gov/study/NCT01945775
Trial related presentations / publications
Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roche HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 Apr 1;28(7):1383-1390. doi: 10.1158/1078-0432.CCR-21-2080.
Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Goncalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01945775